Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30787995 | 1.00 | CCNB2 (0.39) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL2360606 | 0.93 | TP53 (0.43) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL22529406 | 0.93 | TP53 (0.41) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL2359949 | 0.84 | TP53 (0.40) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL2360361 | 0.81 | CCNB2 (0.36) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL2360304 | 0.80 | TP53 (0.40) | TP53CREBBPACHEMAOAALDH1A1 | |
| SCHEMBL8791684 | 0.80 | TP53 (0.60) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL18155436 | 0.76 | TGM2 (0.35) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL2360890 | 0.74 | TP53 (0.39) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL22529425 | 0.74 | TP53 (0.37) | CCNB2CDK1CCNB1GSK3BCCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2531029-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2531029-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
| EP-2531029-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | Radius Health, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097496-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097496-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | CCNB2 4063/4885CDK1 3810/4885CCNB1 3322/4885 |
| US-20170121285-A1 | Selective androgen receptor modulators | AR, SHBG, FSHR | CCNB2 604/4885CDK1 404/4885CCNB1 889/4885 |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, FSHR | CCNB2 603/4885CDK1 398/4885CCNB1 891/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | CCNB2 4063/4885CDK1 3810/4885CCNB1 3322/4885 |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | AR, SHBG, GPR119 | CCNB2 659/4885CDK1 385/4885CCNB1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.